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The incidence rates of malignant tumors increase rapidly in China. Due to the 
complexity of the diseases, the diagnosis usually requires sophisticated technology and 
instruments. The lack of the advanced diagnostic technology cause the problem of “later 
finding time and fewer diagnosis method” during the treatment of malignancy which 
badly delays the timing of the effective clinical decision. At present, “the independent 
molecular pathological lab” is introduced to the cancer treatment in developed markets. 
Compared with other medical institutions, such institutions provide professional and 
advanced technology for clinicians to give medical advices and decisions during the 
treatment. Similar concept in the domestic market is also emerging. The traditional 
medical system of our country, where the hospital set up and own medical laboratory, 
purchasing equipments and recruiting analysts could no longer meet the needs for efficient 
and personalized diagnosis. Hence, we foresee “the independent medical core facility” 
will have a broad market prospect in China.  
The business plan analyzes policy, market, technology and other marco environments 
in diagnostic testing services industry and aims at the establishment of “the third party of 
pathological diagnosis test center” in Xiamen. The feasibility analysis of the project will 
be generated by combining the factors of the marketing decision marking, financial 
situation and human resources which a medical core facility requires. Also this project will 
evaluate the possible risk during introduction period in order to optimize the market 
operation. It will help us to understand the development prospects of this industry and 
bares theoretical significance in business management. 
At present, the wave of “new medical reform” is promoted in the country. It will 
bring a new form of medical institutions and diversified medical service systems. As one 
brand of medical service market, independent medical labs will be affected by this trend. 
This article will talk about the privatization of the operation of medical diagnostic services 
based on the characteristics of medical market, with expect to provide a new idea and 
marketing strategy for private capital investment in the medical industry. 
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